Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic Stroke
- 9 June 2009
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 330 (3), 679-686
- https://doi.org/10.1124/jpet.108.149807
Abstract
Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload. Preclinical research suggests that systemically administered DFO prevents and treats ischemic stroke damage and intracerebral hemorrhage. However, translation into human trials has been limited, probably because of difficulties with DFO administration. A noninvasive method of intranasal administration has emerged recently as a rapid way to bypass the blood-brain barrier and target therapeutic agents to the central nervous system. We report here that intranasal administration targets DFO to the brain and reduces systemic exposure, and that intranasal DFO prevents and treats stroke damage after middle cerebral artery occlusion (MCAO) in rats. A 6-mg dose of DFO resulted in significantly higher DFO concentrations in the brain (0.9–18.5 μM) at 30 min after intranasal administration than after intravenous administration (0.1–0.5 μM, p < 0.05). Relative to blood concentration, intranasal delivery increased targeting of DFO to the cortex approximately 200-fold compared with intravenous delivery. Intranasal administration of three 6-mg doses of DFO did not result in clinically significant changes in blood pressure or heart rate. Pretreatment with intranasal DFO (three 6-mg doses) 48 h before MCAO significantly decreased infarct volume by 55% versus control (p < 0.05). In addition, post-treatment with intranasal administration of DFO (six 6-mg doses) immediately after reperfusion significantly decreased infarct volume by 55% (p < 0.05). These experiments suggest that intranasally administered DFO may be a useful treatment for stroke, and a prophylactic for patients at high risk for stroke.Keywords
This publication has 38 references indexed in Scilit:
- Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseBMC Neuroscience, 2008
- Polyol pathway mediates iron-induced oxidative injury in ischemic–reperfused rat heartFree Radical Biology & Medicine, 2008
- Emerging Medical and Surgical Management Strategies in the Evaluation and Treatment of Intracerebral HemorrhageMayo Clinic Proceedings, 2005
- Desferrioxamine Induces Delayed Tolerance against Cerebral Ischemia in Vivo and in VitroJournal of Cerebral Blood Flow & Metabolism, 2002
- Delivery of125I-NGF to the Brain via the Olfactory RouteDrug Delivery, 1997
- Middle Cerebral Artery Occlusion in the Rat by Intraluminal SutureStroke, 1996
- Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugsToxicology Letters, 1995
- Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats.Stroke, 1994
- Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke, 1989
- Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.Stroke, 1986